Fund moves
8.4%Stake
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ESLA · NASDAQ · Biological Products, (No Diagnostic Substances)
Estrella Immunopharma (ESLA) · oqro.io/stocks/ESLA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Estrella Immunopharma was filed in the last 90 days. The latest on record was on Apr 30, 2026.
Since 2022, Estrella Immunopharma insiders reported 4 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2025.
No open-market sale by an insider of Estrella Immunopharma (ESLA) was filed with the SEC in the last 90 days.
No trade in Estrella Immunopharma (ESLA) was disclosed by a member of Congress in the last 12 months.
Estrella Immunopharma's next results are expected on Mar 16, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.38−0.134 (−26.07%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
−79.6% (−$1.48) from Nov 17, 2025 to Nov 16, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.86 on Nov 17, 2025 to $0.38 on Nov 16, 2026 (−79.6%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Emeryville, Ca.
Last 12 months
−83.3%
Market value
$16.5M
S&P 500 +10.1% over the same dates. Prices adjusted for splits and dividends.
Short interest: 929K shares sold short (2.1% of shares outstanding), +54.9% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $100K, at Jun 30, 2026
Net income, last 12 months
−$10M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Traded Sep 11 – Oct 7, 2025 · largest single transaction ~$1.3K
Sep 22, 2025~$1.2K · 1,000 sh @ $1.16
DetailsOfficial recordOct 7, 2025~$1.3K · 1,000 sh @ $1.33
DetailsOfficial recordSep 11, 2025~$104 · 100 sh @ $1.04
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Fails to deliver: 2.53M shares (about $1.37M) were not delivered on time for settlement on Oct 16, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Insiders of Estrella Immunopharma reported 4 open-market purchases and 0 sales since 2022; purchases in 2 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $2.6K3×3 trades | — |
| 2022 | $44.7B1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in b-cell non-hodgkin's lymphoma (nhl). The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last results
—
Next results, expected
Mar 16, 2027
Purchases after results
Not enough history
From Estrella Immunopharma's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Estrella Immunopharma's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Notice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govSaid its annual or quarterly report would be late
NT 10-Q on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
On the public record for Estrella Immunopharma over the 12 months to Nov 17, 2026: 1 clinical trial.